Trial Profile

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pembrolizumab (Primary) ; Rinatabart sesutecan (Primary)
Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms GCT1184-01/PRO1184-001; RAINFOL-01
Sponsors ProfoundBio

20 Apr 2025 Planned number of patients changed from 404 to 529.
20 Apr 2025 Planned End Date changed from 1 Oct 2026 to 1 sep 2027.
20 Apr 2025 Planned primary completion date changed from 1 Apr 2026 to 1 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com